PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8083115

Improved field edge definition in electron arc therapy with dynamic collimation techniques.

J J Swalec·D D Leavitt·J H Moeller
View original source ↗Export metadata ↓

Abstract

PURPOSE: The diffuse shape of the electron beam used for arc therapy requires collimation on the patient's surface to sharply define treatment field edges. The electron beam arcs 10-15 degrees past field edges defined by a custom fitted and manufactured cast which acts as a tertiary collimator. This allows the entire beam profile to be integrated at the field edge. The tertiary collimator is heavy and bulky, requiring two therapists to lift and position the cast. An alternative technique for field edge definition would require the electron arc collimators to dynamically close to zero, while maintaining the projection of the leading edge of the field coincident with the geometric edge of the treatment field. This would allow integration of the entire electron arc profile and maintain a sharply defined treatment edge at the medial and lateral margins of the arc. The present customized cast could be replaced by generic lead strips at only the superior and inferior treatment field borders. This study investigates the dosimetry of dynamically collimated electron arc treatment volumes at field margins and its potential for eliminating the need for tertiary collimation at the arc field margins. METHODS AND MATERIALS: Electron arc isodose distributions were calculated using a pencil beam algorithm for treatment volumes defined by tertiary collimation at the surface of a cylindrical phantom and compared to distributions generated by simulating dynamic collimation to define the same field edges. Phantom measurements were performed using film densitometry to verify computer predictions. RESULTS: Penumbra width is one measure of the sharpness of dose fall off at a treatment field edge. We define it as the distance between the 90% and 20% isodose lines at the field edge measured orthogonal to the incident electron beam. Calculations and phantom film densitometry measurements were performed for electron energies from 6-20 MeV. Dynamic and tertiary collimation both reduce penumbra width by approximately 50% compared to no collimation. There is a small advantage in minimizing penumbra width at low electron energy with tertiary collimation. This shifts to a small advantage with dynamic collimation at high electron energy. CONCLUSION: Dynamic collimation produces a field edge isodose distribution equivalent to tertiary collimation for clinical purposes. These results suggest that tertiary collimation at medial and lateral electron are treatment field margins can be eliminated with dynamic collimation. This should result in greater clinical acceptance of breast electron arc therapy as the capacity for dynamic collimation is added to the next generation of linear accelerators.

Explore related subjects

Breast NeoplasmsElectronsFemaleHumansRadiation ProtectionRadiotherapy Planning, Computer-AssistedComparative StudyJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J J Swalec, D D Leavitt, J H Moeller. 1994-08-30. Improved field edge definition in electron arc therapy with dynamic collimation techniques.. https://doi.org/10.1016/0360-3016(94)90536-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Hypernetwork-guided fusion with intra-class MixUp for breast cancer subtyping.

Accurate breast cancer subtyping guides treatment selection, yet histopathology captures morphology without molecular state, while genomic profiling captures molecular signatures without spatial context. Existing fusion methods rely on concatenation, or on attention applied only after each modality is encoded independently. This work identifies a scale-dependent asymmetry in the direction of cross-modal conditioning: the direction that performs best under limited samples is not the one that holds at scale, and the reversal is traced to the capacity of the modulation pathway rather than to the fusion principle. The comparison is carried out within a hypernetwork-guided framework in which an auxiliary network maps one modality to conditioning parameters that modulate the other's feature representation, shaping features at the parametric level rather than the decision stage; modulation is patient-specific rather than patch-specific. Both directions are instantiated-gene-to-image (HyperG2I) and image-to-gene (HyperI2G) - and trained under a label-aware MixUp strategy that interpolates within-class samples across both modalities, preserving the hard binary labels clinical decisions require. The framework is evaluated on two paired TCGA-BRCA cohorts-one limited-sample, one independently assembled at scale-under a single protocol spanning two whole-slide representations, multiple visual backbones, and both conditioning directions. On the limited-sample cohort, gene-to-image conditioning at its optimal augmentation setting exceeds early fusion and both unimodal baselines, giving the highest recall on the aggressive Basal/HER2 class of any configuration evaluated, and an ablation favours intra-class over inter-class mixing. At scale this ordering does not hold: image-to-gene conditioning sustains its performance whereas gene-to-image does not, recovering only partially under the full tissue bag and isolating the capacity of the modulation pathway as the binding constraint. Direction and capacity of cross-modal conditioning, rather than fusion depth alone, therefore govern how such frameworks scale.

Breast Neoplasms↗
PubMed2025

Metagenomic analyses reveal E. coli-derived siderophores as potential signatures for breast cancer.

BACKGROUND: Breast cancer remains a leading cause of cancer-related mortality in women. Recent evidence implicates the gut microbiome and metabolites in breast cancer pathogenesis. This study explores associations between gut microbial species, their predicted metabolites, and breast cancer to uncover potential mechanistic insights. METHODS: Comprehensive metagenomic analyses were conducted on the gut microbiome of pre- and postmenopausal breast cancer patients, where microbial species were profiled through AMPHORA2 and metabolites were predicted through antiSMASH. Multivariate association analysis was used to identify significant associations between specific microbial species, predicted metabolites, and breast cancer status. A custom ensemble machine learning classifier was developed to classify pre- and postmenopausal breast cancer cases and controls based on microbial and predicted metabolite features. Additionally, a synthetic microbiome dataset was generated through MIDASim to validate the reproducibility of the ML results. Using our results, we explored the underlying dynamics of identified taxa and metabolite in breast cancer through literature and statistical support. RESULTS: Our analysis identified 471 microbial species and predicted 40 key metabolites in the metagenomic data. Multivariate analysis identified significant positive associations (p-value&#x2009;<&#x2009;0.05) of E. coli, siderophore, and thiopeptide with breast cancer. The custom ensemble model achieved accuracy and AUC as high as 78% and 90%, respectively, in classifying pre- and postmenopausal cases and controls. The high-ranking features i.e., E. coli, siderophore, and thiopeptide were consistent with the results of the multivariate association analysis, thereby substantiating their biological significance. Using these findings, we propose a mechanistic model in which E. coli secretes siderophores under iron-limited conditions in breast cancer patients, for iron sequestration from the host, which can potentially promote angiogenesis and tumor progression. CONCLUSION: Our findings suggest that microbial iron acquisition mechanisms may play a critical role in breast cancer pathophysiology. Functional validation of these mechanisms is needed to assess therapeutic potential. This study highlights gut microbiota and their metabolites as promising targets for breast cancer research and intervention.

Breast Neoplasms↗
PubMed2025

Foundation model based multimodal transformer framework for survival analysis in HER2 stratified breast cancer.

Objective. To improve survival prediction for HER2-positive breast cancer by integrating histopathological, molecular, and clinical data using a multimodal transformer framework.Approach. We propose a multimodal transformer framework for breast cancer survival prediction using HER2 stratified (SurvMBC), a foundation model-enhanced architecture that fuses three data modalities: whole-slide images, clinical narratives, and molecular features. Tumor microenvironment features are extracted using a pathology language and image pre-training (PLIP), clinical narratives are processed with BioBERT, and miRNA expression plus DNA methylation data are embedded using Gen2Vec. These representations are integrated through a cross-modal transformer with attention mechanisms for survival prediction.Main results. The model was evaluated on 1,095 HER2-positive breast cancer patients from The Cancer Genome Atlas. SurvMBC achieved a concordance index (C-index) of 0.857 (95% CI: 0.834, 0.880), a low integrated Brier score, and a strong inverse negative binomial log-likelihood. Risk stratification based on model outputs significantly separated high- and low-risk groups (log-rankp< 0.01) and showed strong associations with tumor stage, grade, and hormone receptor status (allp< 0.05).Significance. SurvMBC demonstrates the effectiveness of multimodal fusion in addressing tumor heterogeneity and improving prognostic accuracy. The attention-based integration enables context-aware learning of survival-relevant features across modalities, supporting individualized risk stratification and risk-adaptive treatment planning for HER2 stratified breast cancer patients.

Breast Neoplasms↗